These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9697676)

  • 1. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.
    Broeders N; Wissing KM; Crusiaux A; Kinnaert P; Vereerstraeten P; Abramowicz D
    J Am Soc Nephrol; 1998 Aug; 9(8):1521-5. PubMed ID: 9697676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine.
    Stegall MD; Simon M; Wachs ME; Chan L; Nolan C; Kam I
    Transplantation; 1997 Dec; 64(12):1695-700. PubMed ID: 9422404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.
    Ruggenenti P; Cravedi P; Gotti E; Plati A; Marasà M; Sandrini S; Bossini N; Citterio F; Minetti E; Montanaro D; Sabadini E; Tardanico R; Martinetti D; Gaspari F; Villa A; Perna A; Peraro F; Remuzzi G
    PLoS Med; 2021 Jun; 18(6):e1003668. PubMed ID: 34166370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil.
    Wüthrich RP; Weinreich T; Ambühl PM; Schwarzkopf AK; Candinas D; Binswanger U
    Nephrol Dial Transplant; 1999 Feb; 14(2):394-9. PubMed ID: 10069195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: A prospective, multicenter, randomized study.
    Sadek S; Medina J; Arias M; Sennesael J; Squifflet JP; Vogt B;
    Transplantation; 2002 Aug; 74(4):511-7. PubMed ID: 12352910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized prospective trial of OKT3 induction in the current immunosuppression era.
    Henry ML; Pelletier RP; Elkhammas EA; Bumgardner GL; Davies EA; Ferguson RM
    Clin Transplant; 2001 Dec; 15(6):410-4. PubMed ID: 11737118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction.
    Smak Gregoor PJ; van Gelder T; van Besouw NM; van der Mast BJ; IJzermans JN; Weimar W
    Transplantation; 2000 Jul; 70(1):143-8. PubMed ID: 10919591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients.
    Wiesner R; Rabkin J; Klintmalm G; McDiarmid S; Langnas A; Punch J; McMaster P; Kalayoglu M; Levy G; Freeman R; Bismuth H; Neuhaus P; Mamelok R; Wang W
    Liver Transpl; 2001 May; 7(5):442-50. PubMed ID: 11349266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Clin Transplant; 2000 Dec; 14(6):561-6. PubMed ID: 11127309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression.
    van der Mast BJ; van Besouw NM; Witvliet MD; de Kuiper P; Smak Gregoor P; van Gelder T; Weimar W; Claas FH
    Transplantation; 2003 Mar; 75(6):871-7. PubMed ID: 12660517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.
    Hesse UJ; Troisi R; Jacobs B; Van Vlem B; de Hemptinne B; Van Holder R; Vermassen F; De Roose J; Lameire N
    Clin Transplant; 2000 Aug; 14(4 Pt 1):340-4. PubMed ID: 10945205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The OKT3 Antibody Response Study: a multicentre study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation.
    Kimball JA; Norman DJ; Shield CF; Schroeder TJ; Lisi P; Garovoy M; O'Connell JB; Stuart F; McDiarmid SV; Wall W
    Transpl Immunol; 1995 Sep; 3(3):212-21. PubMed ID: 8581409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
    Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
    J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.
    Odorico JS; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
    Transplantation; 1998 Dec; 66(12):1751-9. PubMed ID: 9884272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.